ArticleCell reports. Medicine2025

Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy.

Yuan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.